Drug Trial Radar · NCT03789123
Effects of Dienogest and Dienogest Plus Estradiol Valerate in Ovarian Endometrioma
Last checked: Nov 20, 2026Latest source record: Dec 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
710
Planned (sponsor's estimate)
Start
Jan 1, 2019
Primary completion
Jul 1, 2019
Study completion Dec 1, 2019
Sponsor
- Lead sponsor
- Bagcilar Training and Research HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Kocaeli Derince Education and Research Hospital; Suleymaniye Birth And Women's Health Education And Research Hospital
- First posted
- Dec 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Progesterone resistance in endometriosis is a known fact. The progestin derivatives used in endometriosis cause decidualization and atrophy of ectopic foci. Moreover, they inhibit neo-angiogenesis, provide suppress expansile/destructive growth facilitated by matrix metalloproteinases, and implantation of ectopic foci. The effect of drugs containing the estrogen-progesterone combination is mainly based on the inhibition of ovulation, decidualization and atrophy of ectopic foci. In estrogen-progesterone mechanism, it is known that estrogen has a progesterone receptor-enhancing effect, which may make progesterone more potent. Based on this, the investigators hypothesized that estrogen added to progesterone could lead to a further reduction in endometrioma size by various mechanisms which probably include the increased progesterone sensitivity in endometriosis. In addition, the investigators hypothesized that this therapy can alleviate the destructive effect of endometriomas on the ovarian reserve.
Conditions
- Ovarian Reserve
Interventions
Estradiol valerate/dienogestDrug
The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ovarian reserveTime frame: up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tolga Karacan
Istanbul, Bagcilar, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.